0914 GMT - Sanofi's revised hospital drug-discount program in the U.S. holds long-term promise, although industry-wide implementation hurdles persist, Bryan Garnier Health analysts say in a note. The U.S. federal program, known as 340B and aimed at vulnerable patients, is increasingly used by hospitals to profit by charging the drugs' list prices while purchasing them at a discount, the analysts say. Under its new plan, Sanofi requires institutions to provide medical claims information before receiving discounts. Eli Lilly and Johnson & Johnson this month sued the federal government for rejecting similar rebate proposals. Sanofi reported in 2023 that discounts under Medicare and 340B led to a 15.7% decrease in its portfolio net price. Shares fall 0.3% to 92.89 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
November 25, 2024 04:15 ET (09:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。